The Urothelial Carcinoma Market was valued at USD 3.5 billion in 2024 and is projected to reach USD 7.1 billion by 2034, registering a CAGR of 7.5%. This growth trajectory is underpinned by several key factors, including the rising prevalence of urothelial carcinoma, advancements in treatment modalities, and increasing awareness regarding early diagnosis and treatment options. The market is...